Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
PURPOSE: Filtration failure due to excessive postoperative scarring remains a major problem after glaucoma surgery. The authors have investigated whether glaucoma and filtration surgery are associated with increased levels of vascular endothelial growth factor (VEGF), and whether a humanized monoclonal antibody against VEGF, bevacizumab, can reduce postoperative scar formation and improve surgical outcome. METHODS: The levels of VEGF in samples of aqueous humor were measured by ELISA. The expression of the VEGF receptors Flt-1 and KDR was analyzed in cultured Tenon fibroblasts by real-time RT-PCR and Western blotting. The effect of VEGF and bevacizumab on Tenon fibroblasts in vitro was determined using a proliferation assay. The in vivo effect of the antibody was investigated in a rabbit model of trabeculectomy by measuring the intraocular pressure (IOP) and bleb area, and by immunohistological analysis of angiogenesis, inflammation, and fibrosis. RESULTS: VEGF levels were increased significantly in the aqueous humor of glaucoma patients and rabbits that had undergone surgery. Both VEGF receptors were expressed on Tenon fibroblasts. Fibroblast proliferation in vitro was stimulated by delivery of VEGF, and was inhibited by administration of bevacizumab. The antibody also reduced angiogenesis and collagen deposition significantly, and improved the outcome of glaucoma surgery in rabbits. CONCLUSIONS: VEGF was upregulated in the aqueous humor of glaucoma patients and in the rabbit model, and it stimulated fibroblast proliferation in vitro. This suggests that it is involved in the scarring process after filtration surgery. Bevacizumab reduced the proliferation of fibroblasts in vitro and improved surgical outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bevacizumab is reported to have antifibrotic activity that reduces scar formation in glaucoma filtration surgery.29–31”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [30]
Citations
Cites
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Self-citationAiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,672
Self-citationTonnesen, M. G., Feng, X., & Clark, R. A. F. (2000) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1087-0024.2000.00014.x · Cited by 1,463
Stone, J., Itin, A., Alon, T., Pe'er, J., Gnessin, H., Chan-Ling, T., & Keshet, E. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-07-04738.1995 · Cited by 1,006
Nissen, N., Polverini, P. J., Koch, A. E., Volin, M. V., Gamelli, R. L., & DiPietro, L. A. (1998) · Europe PMC (PubMed Central) · Cited by 965
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Self-citationPertovaara, L., Kaipainen, A., Mustonen, T., Orpana, A., Ferrara, N., Saksela, O., & Alitalo, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37365-9 · Cited by 694
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Aqueous Humor in Glaucomatous Eyes Contains an Increased Level of TGF-β2
Tripathi, R. C., Li, J., Chan, W. A., & Tripathi, B. J. (1994) · Experimental Eye Research · doi:10.1006/exer.1994.1158 · Cited by 566
Cited by
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
PCL-PEG copolymer based injectable thermosensitive hydrogels
Dethe, M. R., A, P., Ahmed, H., Agrawal, M., Roy, U., & Alexander, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.035 · Cited by 263
Propolis: An update on its chemistry and pharmacological applications
Hossain, R., Quispe, C., Khan, R. A., Saikat, A. S. M., Ray, P., Ongalbek, D., Yeskaliyeva, B., Jain, D., Smeriglio, A., Trombetta, D., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00651-2 · Cited by 215
Research progress on the mechanism of angiogenesis in wound repair and regeneration
Shi, Z., Yao, C., Shui, Y., Li, S., & Yan, H. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1284981 · Cited by 183
The surgical management of glaucoma: A review
Lim, R. (2022) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14028 · Cited by 179
Metadata
- Authors
- Li, Z., Van Bergen, T., Van de Veire, S., Van de Vel, I., Moreau, H., Dewerchin, M., Maudgal, P. C., Zeyen, T., Spileers, W., Moons, L., & Stalmans, I.
- Affiliations
- Capital Medical University (CN)
- From the Laboratory of Ophthalmology, and
- From the Laboratory of Ophthalmology, and 4Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium;
- ThromboGenics NV, Leuven, Belgium;
- Vlaams Instituut voor Biotechnologie (BE)
- Universitair Ziekenhuis Leuven (BE)
- KU Leuven (BE)
- Corresponding author
- Li, Zhongqiu
- Moreau, Huberte
- Dewerchin, Mieke
- Maudgal, Prabhat C.
- Zeyen, Thierry
- Spileers, Werner
- Moons, Lieve
- Stalmans, Ingeborg
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2009-11-01
- Volume
- 50
- Issue
- 11
- Pages
- 5217
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2004845166
- Cited by
- 223
- References
- 55
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 5 · 2023: 19 · 2022: 11 · 2021: 9 · 2020: 18 · 2019: 16 · 2018: 11 · 2017: 16 · 2016: 16 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 19
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Corneal surgery and disorders
- Health Sciences › Medicine › Ophthalmology › Intraocular Surgery and Lenses
- Keywords
- vascular endothelial growth factor, bevacizumab, glaucoma filtration surgery, trabeculectomy, postoperative scarring, aqueous humor, Tenon fibroblasts, VEGF receptors, angiogenesis, fibrosis, collagen deposition, intraocular pressure, blebs
- MeSH terms
- Bevacizumab, Animals, Anterior Chamber, Antibodies, Monoclonal, Aqueous Humor, Cells, Cultured, Cicatrix, Conjunctival Diseases, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Female, Fibroblasts, Glaucoma, Open-Angle, Humans, Injections, Intraocular Pressure, Postoperative Complications, Rabbits, Tonometry, Ocular, Trabeculectomy, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Cell Proliferation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.